UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase I Trial of Intravesical Recombinant Adenovirus Mediated Interferon-α2b Formulated in Syn3 for Bacillus Calmette-Guérin Failures in Nonmuscle Invasive Bladder Cancer

The Journal of urology, 2013-09, Vol.190 (3), p.850-856

2013

Volltextzugriff (PDF)

EVIDENCE SUPPORTING PREOPERATIVE CHEMOTHERAPY FOR SMALL CELL CARCINOMA OF THE BLADDER: A RETROSPECTIVE REVIEW OF THE M. D. ANDERSON CANCER EXPERIENCE

The Journal of urology, 2004-08, Vol.172 (2), p.481-484

2004

Volltextzugriff (PDF)

Association of polymorphisms in oxidative stress genes with clinical outcomes for bladder cancer treated with Bacillus Calmette-Guérin

PloS one, 2012-06, Vol.7 (6), p.e38533

2012

Volltextzugriff (PDF)

Considerations on the use of urine markers in the management of patients with high-grade non–muscle-invasive bladder cancer

Urologic oncology, 2014-10, Vol.32 (7), p.1069-1077

2014

Volltextzugriff (PDF)

Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer

Nature reviews. Urology, 2015-04, Vol.12 (4), p.225

2015

Volltextzugriff (PDF)

Micropapillary bladder cancer : A review of the University of Texas M. D. Anderson cancer center experience with 100 consecutive patients

Cancer, 2007-07, Vol.110 (1), p.62-67

2007

Volltextzugriff (PDF)

Forced COX-2 expression induces PGE2 and invasion in immortalized urothelial cells

Urologic oncology, 2008-11, Vol.26 (6), p.641-645

2008

Volltextzugriff (PDF)

Phase 1b Trial to Evaluate Tissue Response to a Second Dose of Intravesical Recombinant Adenoviral Interferon α2b Formulated in Syn3 for Failures of Bacillus Calmette–Guerin (BCG) Therapy in Nonmuscle Invasive Bladder Cancer

Annals of surgical oncology, 2016-11, Vol.23 (12), p.4110-4114

2016

Volltextzugriff (PDF)

Commentary on “International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: Long-term results of the BA06 30894 trial.” Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK, and the International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group); European Organization for Research and Treatm

Urologic oncology, 2012-03, Vol.30 (2), p.226-226

Grossman, H. Barton, M.D

2012

Volltextzugriff (PDF)

Commentary on “Long-term use of supplemental vitamins and minerals does not reduce the risk of urothelial cell carcinoma of the bladder in the VITamins And Lifestyle study.” Hotaling JM, Wright JL, Pocobelli G, Bhatti P, Porter MP, White E, Department of Urology, University of Washington School of Medicine, Seattle, Washington 98103, USA

Urologic oncology, 2012-03, Vol.30 (2), p.226-227

Grossman, H. Barton, M.D

2012

Volltextzugriff (PDF)

Commentary on “Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04–75.” Hahn NM, Stadler WM, Zon RT, Waterhouse D, Picus J, Nattam S, Johnson CS, Perkins SM, Waddell MJ, Sweeney CJ; Hoosier Oncology Group, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

Urologic oncology, 2012-03, Vol.30 (2), p.228-229

Grossman, H. Barton, M.D

2012

Volltextzugriff (PDF)

Commentary on “Paclitaxel gelatin nanoparticles for intravesical bladder cancer therapy.” Lu Z, Yeh TK, Wang J, Chen L, Lyness G, Xin Y, Wientjes MG, Bergdall V, Couto G, Alvarez-Berger F, Kosarek CE, Au JL, Optimum Therapeutics, L.L.C., Columbus, OH

Urologic oncology, 2012-03, Vol.30 (2), p.228-228

Grossman, H. Barton, M.D

2012

Volltextzugriff (PDF)

Commentary on “Select screening in a specific high-risk population of patients suggests a stage migration toward detection of non-muscle-invasive bladder cancer.” Zlotta AR, Roumeguere T, Kuk C, Alkhateeb S, Rorive S, Lemy A, van der Kwast TH, Fleshner NE, Jewett MA, Finelli A, Schulman C, Lotan Y, Shariat SF, Nortier J, Division of Urology, Mount Sinai Hospital, Toronto, Canada

Urologic oncology, 2012-03, Vol.30 (2), p.229-229

Grossman, H. Barton, M.D

2012

Volltextzugriff (PDF)

Commentary on “Trends in hospital volume and operative mortality for high-risk surgery.” Finks JF, Osborne NH, Birkmeyer JD, Center for Healthcare Outcomes and Policy and the Section of General Surgery, Department of Surgery, University of Michigan, Ann Arbor, MI

Urologic oncology, 2012-03, Vol.30 (2), p.227-227

Grossman, H. Barton, M.D

2012

Volltextzugriff (PDF)

Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder: a contemporary review of The University of Texas M D Anderson Cancer Center experience

Cancer, 2007-08, Vol.110 (4), p.764-769

2007

Volltextzugriff (PDF)

Outcome of Patients With Bladder Cancer With pN+ Disease After Preoperative Chemotherapy and Radical Cystectomy

Urology (Ridgewood, N.J.), 2009, Vol.73 (1), p.147-152

2009

Volltextzugriff (PDF)

Editorial Comment

The Journal of urology, 2018-10, Vol.200 (4), p.748-748

Grossman, H. Barton

2018

Volltextzugriff (PDF)

Erratum to: The UBC-40 Urothelial Bladder Cancer Cell Line Index: a genomic resource for functional studies

BMC genomics, 2015-11, Vol.16 (1), p.1019-1019, Article 1019

2015

Volltextzugriff (PDF)

Erratum to: The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies

BMC genomics, 2016-10, Vol.17 (1), p.829, Article 829

2016

Volltextzugriff (PDF)

Words of wisdom. Re: radical cystectomy with extended lymphadenectomy: evaluating separate package versus en bloc submission for node positive bladder cases

European urology, 2007-12, Vol.52 (6), p.1798-1798

Grossman, H Barton

2007

Volltextzugriff (PDF)

P0 Stage at Radical Cystectomy for Bladder Cancer is Associated with Improved Outcome Independent of Traditional Clinical Risk Factors

European urology, 2007-09, Vol.52 (3), p.769-776

2007

Volltextzugriff (PDF)

Editorial Comment

The Journal of urology, 2017-06, Vol.197 (6), p.1417-1417

Grossman, H. Barton

2017

Volltextzugriff (PDF)

Editorial Comment

The Journal of urology, 2017

Grossman, H. Barton

2017

Volltextzugriff (PDF)

Glutathione peroxidase 1 gene polymorphism and risk of recurrence in patients with superficial bladder cancer

Urology (Ridgewood, N.J.), 2005-10, Vol.66 (4), p.769-774

2005

Volltextzugriff (PDF)

Commentary on Surgery for metastatic urothelial carcinoma with curative intent: The German experience (AUO AB 30/05)

Urologic oncology, 2009, Vol.27 (3), p.339-339

Grossman, H. Barton, M.D

2009

Volltextzugriff (PDF)

1 – 25 von 271

Suche als RSS-Feed

Aktive Filter

ThemaLife Sciences & Biomedicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(259)
Mit Volltextzugriff
(140)

Publikationsform

Sprache

Englisch
(270)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Urology
(55)
Biological And Medical Sciences
(50)
Medical Sciences
(48)
Nephrology. Urinary Tract Diseases
(44)
Tumors Of The Urinary System
(34)
Urinary Tract. Prostate Gland
(34)
Humans
(32)
Urinary System Involvement In Other Diseases. Miscellaneous
(22)
Male
(20)
Bladder Cancer
(15)
Aged
(13)
Middle Aged
(13)
Female
(12)
Cystectomy
(10)
Urinary Bladder Neoplasms - Pathology
(10)
Adult
(9)
Aged, 80 And Over
(8)
Carcinoma, Transitional Cell - Pathology
(7)
Urinary Bladder Neoplasms - Drug Therapy
(7)
Chemotherapy
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

The Journal Of Urology
(120)
Urologic Oncology
(36)
The journal Of Urology/the journal Of Urology
(16)
Urology
(15)
Cancer
(12)
Journal Of Clinical Oncology
(11)
Cancer Research
(7)
European Urology
(6)
Annals Of Surgical Oncology
(3)
Cancer Prevention Research
(3)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Phase I Trial of Intravesical Recombinant Adenovirus Mediated Interferon-α2b Formulated in Syn3 for Bacillus Calmette-Guérin Failures in Nonmuscle Invasive Bladder Cancer

EVIDENCE SUPPORTING PREOPERATIVE CHEMOTHERAPY FOR SMALL CELL CARCINOMA OF THE BLADDER: A RETROSPECTIVE REVIEW OF THE M. D. ANDERSON CANCER EXPERIENCE

Association of polymorphisms in oxidative stress genes with clinical outcomes for bladder cancer treated with Bacillus Calmette-Guérin

Considerations on the use of urine markers in the management of patients with high-grade non–muscle-invasive bladder cancer

Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer

Micropapillary bladder cancer : A review of the University of Texas M. D. Anderson cancer center experience with 100 consecutive patients

Forced COX-2 expression induces PGE2 and invasion in immortalized urothelial cells

Phase 1b Trial to Evaluate Tissue Response to a Second Dose of Intravesical Recombinant Adenoviral Interferon α2b Formulated in Syn3 for Failures of Bacillus Calmette–Guerin (BCG) Therapy in Nonmuscle Invasive Bladder Cancer

Commentary on “Paclitaxel gelatin nanoparticles for intravesical bladder cancer therapy.” Lu Z, Yeh TK, Wang J, Chen L, Lyness G, Xin Y, Wientjes MG, Bergdall V, Couto G, Alvarez-Berger F, Kosarek CE, Au JL, Optimum Therapeutics, L.L.C., Columbus, OH

Commentary on “Trends in hospital volume and operative mortality for high-risk surgery.” Finks JF, Osborne NH, Birkmeyer JD, Center for Healthcare Outcomes and Policy and the Section of General Surgery, Department of Surgery, University of Michigan, Ann Arbor, MI

Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder: a contemporary review of The University of Texas M D Anderson Cancer Center experience

Outcome of Patients With Bladder Cancer With pN+ Disease After Preoperative Chemotherapy and Radical Cystectomy

Editorial Comment

Erratum to: The UBC-40 Urothelial Bladder Cancer Cell Line Index: a genomic resource for functional studies

Erratum to: The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies

Words of wisdom. Re: radical cystectomy with extended lymphadenectomy: evaluating separate package versus en bloc submission for node positive bladder cases

P0 Stage at Radical Cystectomy for Bladder Cancer is Associated with Improved Outcome Independent of Traditional Clinical Risk Factors

Editorial Comment

Editorial Comment

Glutathione peroxidase 1 gene polymorphism and risk of recurrence in patients with superficial bladder cancer

Commentary on Surgery for metastatic urothelial carcinoma with curative intent: The German experience (AUO AB 30/05)

Aktive Filter

Suchergebnisse filtern